[
  {
    "ts": null,
    "headline": "Eli Lilly (LLY) Laps the Stock Market: Here's Why",
    "summary": "Eli Lilly (LLY) closed the most recent trading day at $839.87, moving +2.44% from the previous trading session.",
    "url": "https://finnhub.io/api/news?id=97ef74947bab0695be2d8ea1d58ba846b3f5922ff9c62bd4fc83d464414f5a37",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1759527903,
      "headline": "Eli Lilly (LLY) Laps the Stock Market: Here's Why",
      "id": 136980574,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "LLY",
      "source": "Yahoo",
      "summary": "Eli Lilly (LLY) closed the most recent trading day at $839.87, moving +2.44% from the previous trading session.",
      "url": "https://finnhub.io/api/news?id=97ef74947bab0695be2d8ea1d58ba846b3f5922ff9c62bd4fc83d464414f5a37"
    }
  },
  {
    "ts": null,
    "headline": "US Equity Indexes Rise This Week as AI-Trade Lifts Tech, Healthcare Gains Following Pfizer Deal",
    "summary": "US equity indexes ended higher this week as a federal government shutdown in its early days failed t",
    "url": "https://finnhub.io/api/news?id=6b62ac183b5a695c26807571dc66235f3c095bc9b6f389696fe9ff0940d3a2c8",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1759525126,
      "headline": "US Equity Indexes Rise This Week as AI-Trade Lifts Tech, Healthcare Gains Following Pfizer Deal",
      "id": 136980575,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "LLY",
      "source": "Yahoo",
      "summary": "US equity indexes ended higher this week as a federal government shutdown in its early days failed t",
      "url": "https://finnhub.io/api/news?id=6b62ac183b5a695c26807571dc66235f3c095bc9b6f389696fe9ff0940d3a2c8"
    }
  },
  {
    "ts": null,
    "headline": "5 Large Cap Drug Stocks: Values or Traps?",
    "summary": "Some drug stocks are cheap but is it another fake out?",
    "url": "https://finnhub.io/api/news?id=6b37ae979ad1261a96d773275c84229ccfdaabe06d40dae948855552f983204c",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1759524900,
      "headline": "5 Large Cap Drug Stocks: Values or Traps?",
      "id": 136980576,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "LLY",
      "source": "Yahoo",
      "summary": "Some drug stocks are cheap but is it another fake out?",
      "url": "https://finnhub.io/api/news?id=6b37ae979ad1261a96d773275c84229ccfdaabe06d40dae948855552f983204c"
    }
  },
  {
    "ts": null,
    "headline": "Eli Lilly & Co. stock outperforms competitors on strong trading day",
    "summary": "Eli Lilly & Co. stock outperforms competitors on strong trading day",
    "url": "https://finnhub.io/api/news?id=540e9abd57b65034fc0f4f506206ebdfa28ec83fb6b12c5c4c8c148aadbad882",
    "source": "MarketWatch",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1759509060,
      "headline": "Eli Lilly & Co. stock outperforms competitors on strong trading day",
      "id": 136995474,
      "image": "",
      "related": "LLY",
      "source": "MarketWatch",
      "summary": "Eli Lilly & Co. stock outperforms competitors on strong trading day",
      "url": "https://finnhub.io/api/news?id=540e9abd57b65034fc0f4f506206ebdfa28ec83fb6b12c5c4c8c148aadbad882"
    }
  },
  {
    "ts": null,
    "headline": "Pharmaceutical Stocks: Valuations And Pipelines Are Only Beginning To Be Appreciated",
    "summary": "Discover why drug stocks like LLY, NVO, AZN & PFE could outperform in 2025 amid strong healthcare trends. Click for my picks.",
    "url": "https://finnhub.io/api/news?id=39054aec8ba10e961ea96a273ddee36fc4c99bf71a99023c0844a605f6cc98ae",
    "source": "SeekingAlpha",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1759508459,
      "headline": "Pharmaceutical Stocks: Valuations And Pipelines Are Only Beginning To Be Appreciated",
      "id": 136967001,
      "image": "https://static.seekingalpha.com/cdn/s3/uploads/getty_images/2212761810/image_2212761810.jpg?io=getty-c-w1536",
      "related": "LLY",
      "source": "SeekingAlpha",
      "summary": "Discover why drug stocks like LLY, NVO, AZN & PFE could outperform in 2025 amid strong healthcare trends. Click for my picks.",
      "url": "https://finnhub.io/api/news?id=39054aec8ba10e961ea96a273ddee36fc4c99bf71a99023c0844a605f6cc98ae"
    }
  },
  {
    "ts": null,
    "headline": "Palantir, AI bubble comments, pharma stocks: Trending Tickers",
    "summary": "Market Catalysts host Julie Hyman and Yahoo Finance senior reporter Allie Canal track several of the day's top trending stock tickers, including Palantir Technologies (PLTR) receiving pushback from Dutch lawmakers, commentary around an AI bubble from top executives, and pharmaceutical stocks — which includes Pfizer (PFE) — set to cap their best trading week in 16 years. To watch more expert insights and analysis on the latest market action, check out more Market Catalysts.",
    "url": "https://finnhub.io/api/news?id=e133b8ef1ef28dc49f1289456a1433ec675317e6785a72400f568b4c5394c051",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1759506534,
      "headline": "Palantir, AI bubble comments, pharma stocks: Trending Tickers",
      "id": 136980578,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "LLY",
      "source": "Yahoo",
      "summary": "Market Catalysts host Julie Hyman and Yahoo Finance senior reporter Allie Canal track several of the day's top trending stock tickers, including Palantir Technologies (PLTR) receiving pushback from Dutch lawmakers, commentary around an AI bubble from top executives, and pharmaceutical stocks — which includes Pfizer (PFE) — set to cap their best trading week in 16 years. To watch more expert insights and analysis on the latest market action, check out more Market Catalysts.",
      "url": "https://finnhub.io/api/news?id=e133b8ef1ef28dc49f1289456a1433ec675317e6785a72400f568b4c5394c051"
    }
  },
  {
    "ts": null,
    "headline": "Morgan Stanley Maintains Eli Lilly and (LLY) Overweight Recommendation",
    "summary": "Morgan Stanley Maintains Eli Lilly and (LLY) Overweight Recommendation",
    "url": "https://finnhub.io/api/news?id=67cf5e49dfed23829311ed3ca11eb7602e57613318f9c8b3c3288fc298438aa8",
    "source": "Fintel",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1759503963,
      "headline": "Morgan Stanley Maintains Eli Lilly and (LLY) Overweight Recommendation",
      "id": 136965300,
      "image": "",
      "related": "LLY",
      "source": "Fintel",
      "summary": "",
      "url": "https://finnhub.io/api/news?id=67cf5e49dfed23829311ed3ca11eb7602e57613318f9c8b3c3288fc298438aa8"
    }
  },
  {
    "ts": null,
    "headline": "Why Shares of Eli Lilly Soared This Week",
    "summary": "Pfizer's deal with the Trump administration raised hopes that Eli Lilly would also avoid pharmaceutical tariffs.",
    "url": "https://finnhub.io/api/news?id=821e73c1ea3325030951ea371e9c82949606408e5cb4332c3c450c25972c7b7e",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1759502820,
      "headline": "Why Shares of Eli Lilly Soared This Week",
      "id": 136965071,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "LLY",
      "source": "Yahoo",
      "summary": "Pfizer's deal with the Trump administration raised hopes that Eli Lilly would also avoid pharmaceutical tariffs.",
      "url": "https://finnhub.io/api/news?id=821e73c1ea3325030951ea371e9c82949606408e5cb4332c3c450c25972c7b7e"
    }
  },
  {
    "ts": null,
    "headline": "MRK Stock Up Nearly 14% So Far This Week: What's Driving It?",
    "summary": "Merck shares climb nearly 14% as Pfizer's landmark drug pricing deal with the Trump administration sparked renewed optimism in pharma stocks.",
    "url": "https://finnhub.io/api/news?id=8e49fe92f5a0728e930c52ffc1547ef9d062a15b03767bf598e48c84d6c4fc85",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1759500360,
      "headline": "MRK Stock Up Nearly 14% So Far This Week: What's Driving It?",
      "id": 136980579,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "LLY",
      "source": "Yahoo",
      "summary": "Merck shares climb nearly 14% as Pfizer's landmark drug pricing deal with the Trump administration sparked renewed optimism in pharma stocks.",
      "url": "https://finnhub.io/api/news?id=8e49fe92f5a0728e930c52ffc1547ef9d062a15b03767bf598e48c84d6c4fc85"
    }
  },
  {
    "ts": null,
    "headline": "Is PFE Stock a Buy After 14% Rise Post Drug Pricing Deal With Trump?",
    "summary": "Pfizer surges 14% after landmark Trump deal slashing drug prices while boosting U.S. investments.",
    "url": "https://finnhub.io/api/news?id=efa23a72bc7c155f7e813fa90c5b87573487e3e25ce5bc0f38399ad887aff7a9",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1759499940,
      "headline": "Is PFE Stock a Buy After 14% Rise Post Drug Pricing Deal With Trump?",
      "id": 136980580,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "LLY",
      "source": "Yahoo",
      "summary": "Pfizer surges 14% after landmark Trump deal slashing drug prices while boosting U.S. investments.",
      "url": "https://finnhub.io/api/news?id=efa23a72bc7c155f7e813fa90c5b87573487e3e25ce5bc0f38399ad887aff7a9"
    }
  },
  {
    "ts": null,
    "headline": "Structure Therapeutics: The Dark Horse In The Oral Obesity GLP-1 Arena",
    "summary": "Structure Therapeutics Inc. is a clinical-stage biotech focused on oral GLP-1 drugs for obesity, targeting a rapidly growing sector in pharma market. Learn more about GPCR stock here.",
    "url": "https://finnhub.io/api/news?id=ed0f4a1dfebc13f9a887aac9c92ace202289cd3139f4b2fc607abd0cfaeb024a",
    "source": "SeekingAlpha",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1759499223,
      "headline": "Structure Therapeutics: The Dark Horse In The Oral Obesity GLP-1 Arena",
      "id": 136966164,
      "image": "https://static.seekingalpha.com/cdn/s3/uploads/getty_images/1334867021/image_1334867021.jpg?io=getty-c-w1536",
      "related": "LLY",
      "source": "SeekingAlpha",
      "summary": "Structure Therapeutics Inc. is a clinical-stage biotech focused on oral GLP-1 drugs for obesity, targeting a rapidly growing sector in pharma market. Learn more about GPCR stock here.",
      "url": "https://finnhub.io/api/news?id=ed0f4a1dfebc13f9a887aac9c92ace202289cd3139f4b2fc607abd0cfaeb024a"
    }
  },
  {
    "ts": null,
    "headline": "Analyst Explains Why Eli Lilly (LLY) GLP-1 Advantage is Decreasing",
    "summary": "We recently published 10 Stocks to Watch Ahead of Q3 Earnings Season. Eli Lilly and Company (NYSE:LLY) is one of the stocks that Wall Street analysts are discussing these days. Don Kaufman of TheoTrade said in a recent program on Schwab Network that Eli Lilly And Co (NYSE:LLY) edge in the GLP-1 drugs is thinning […]",
    "url": "https://finnhub.io/api/news?id=91822bbed2ad1cc4d4b4eb86c6dac8575a89787908ca0e68e5753f7f7a075374",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1759498736,
      "headline": "Analyst Explains Why Eli Lilly (LLY) GLP-1 Advantage is Decreasing",
      "id": 136965072,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "LLY",
      "source": "Yahoo",
      "summary": "We recently published 10 Stocks to Watch Ahead of Q3 Earnings Season. Eli Lilly and Company (NYSE:LLY) is one of the stocks that Wall Street analysts are discussing these days. Don Kaufman of TheoTrade said in a recent program on Schwab Network that Eli Lilly And Co (NYSE:LLY) edge in the GLP-1 drugs is thinning […]",
      "url": "https://finnhub.io/api/news?id=91822bbed2ad1cc4d4b4eb86c6dac8575a89787908ca0e68e5753f7f7a075374"
    }
  },
  {
    "ts": null,
    "headline": "Pharma Stocks Eye Best Week in 16 Years as Trump Overhang Eases",
    "summary": "The group’s advance was spurred by Pfizer Inc. on Tuesday when it agreed to slash some of its drug prices for Americans enrolled in the Medicaid insurance program in exchange for a three-year reprieve on import tariffs.  The New York-based company also agreed to invest $70 billion in the US as part of an agreement with President Donald Trump.  The deal was seen as another sign of easing pressures on the pharmaceutical industry since the president announced possible future tariffs on drug imports in April as well as drug-pricing reforms in May. It followed Trump’s move last week to exempt companies with US manufacturing from pharmaceutical levies in the first signal of relief for the sector.",
    "url": "https://finnhub.io/api/news?id=4ed048c0b8b53dcf134371fcbdd5cfdf7bfe39a5a8cc056485e84b9d971547e8",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1759498087,
      "headline": "Pharma Stocks Eye Best Week in 16 Years as Trump Overhang Eases",
      "id": 136965073,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "LLY",
      "source": "Yahoo",
      "summary": "The group’s advance was spurred by Pfizer Inc. on Tuesday when it agreed to slash some of its drug prices for Americans enrolled in the Medicaid insurance program in exchange for a three-year reprieve on import tariffs.  The New York-based company also agreed to invest $70 billion in the US as part of an agreement with President Donald Trump.  The deal was seen as another sign of easing pressures on the pharmaceutical industry since the president announced possible future tariffs on drug imports in April as well as drug-pricing reforms in May. It followed Trump’s move last week to exempt companies with US manufacturing from pharmaceutical levies in the first signal of relief for the sector.",
      "url": "https://finnhub.io/api/news?id=4ed048c0b8b53dcf134371fcbdd5cfdf7bfe39a5a8cc056485e84b9d971547e8"
    }
  },
  {
    "ts": null,
    "headline": "Kernal Bio Joins Lilly Gateway Labs to Accelerate In Vivo Cell Therapies",
    "summary": "BOSTON, October 03, 2025--Kernal Bio retains strategic independence, while gaining access to shared resources, operational support and Lilly’s global network of experts.",
    "url": "https://finnhub.io/api/news?id=4c8b7003cd13097d29ea07194af51a97c1c1adaa22b471f2d3f44dec3c937af2",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1759496400,
      "headline": "Kernal Bio Joins Lilly Gateway Labs to Accelerate In Vivo Cell Therapies",
      "id": 136964289,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "LLY",
      "source": "Yahoo",
      "summary": "BOSTON, October 03, 2025--Kernal Bio retains strategic independence, while gaining access to shared resources, operational support and Lilly’s global network of experts.",
      "url": "https://finnhub.io/api/news?id=4c8b7003cd13097d29ea07194af51a97c1c1adaa22b471f2d3f44dec3c937af2"
    }
  },
  {
    "ts": null,
    "headline": "Top 50 High-Quality Dividend Growth Stocks For October 2025",
    "summary": "A list of top dividend growth stocks for 2025 with strong return potential is provided. See which undervalued picks offer the best blend of yield and growth.",
    "url": "https://finnhub.io/api/news?id=9c78efb85c861b39623e6f935effc4add6f3514e693a00435ac22aafd8745797",
    "source": "SeekingAlpha",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1759488387,
      "headline": "Top 50 High-Quality Dividend Growth Stocks For October 2025",
      "id": 136964924,
      "image": "https://static.seekingalpha.com/cdn/s3/uploads/getty_images/2224990654/image_2224990654.jpg?io=getty-c-w1536",
      "related": "LLY",
      "source": "SeekingAlpha",
      "summary": "A list of top dividend growth stocks for 2025 with strong return potential is provided. See which undervalued picks offer the best blend of yield and growth.",
      "url": "https://finnhub.io/api/news?id=9c78efb85c861b39623e6f935effc4add6f3514e693a00435ac22aafd8745797"
    }
  },
  {
    "ts": null,
    "headline": "Eli Lilly and Company (LLY) Gets Upgraded to a Buy by CFRA",
    "summary": "Eli Lilly and Company (NYSE:LLY) is one of the best medical stocks to buy now. In a report released on September 26, CFRA upgraded Eli Lilly and Company (NYSE:LLY) to a Buy, setting a price target of $835.00. Eli Lilly and Company (NYSE:LLY) reported a 38% growth in its revenue for fiscal Q2 2025 to […]",
    "url": "https://finnhub.io/api/news?id=79d132ffa4e5bc105455798a096d956276c97b884f1cd0403c2879bc466c0d5b",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1759487268,
      "headline": "Eli Lilly and Company (LLY) Gets Upgraded to a Buy by CFRA",
      "id": 136963169,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "LLY",
      "source": "Yahoo",
      "summary": "Eli Lilly and Company (NYSE:LLY) is one of the best medical stocks to buy now. In a report released on September 26, CFRA upgraded Eli Lilly and Company (NYSE:LLY) to a Buy, setting a price target of $835.00. Eli Lilly and Company (NYSE:LLY) reported a 38% growth in its revenue for fiscal Q2 2025 to […]",
      "url": "https://finnhub.io/api/news?id=79d132ffa4e5bc105455798a096d956276c97b884f1cd0403c2879bc466c0d5b"
    }
  },
  {
    "ts": null,
    "headline": "Novartis: Superstars Entresto And Kisqali Fuel Market Outperformance",
    "summary": "Novartis shines with oncology growth, strong buybacks, and a $1.4B heart drug acquisition, defying headwinds like Entresto generics. Read why NVS stock is a buy.",
    "url": "https://finnhub.io/api/news?id=19544720167cb57ffae0079873d350c27432d55c7a1bc442759b979b242ebbe6",
    "source": "SeekingAlpha",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1759481800,
      "headline": "Novartis: Superstars Entresto And Kisqali Fuel Market Outperformance",
      "id": 136964031,
      "image": "https://static.seekingalpha.com/cdn/s3/uploads/getty_images/1304608112/image_1304608112.jpg?io=getty-c-w1536",
      "related": "LLY",
      "source": "SeekingAlpha",
      "summary": "Novartis shines with oncology growth, strong buybacks, and a $1.4B heart drug acquisition, defying headwinds like Entresto generics. Read why NVS stock is a buy.",
      "url": "https://finnhub.io/api/news?id=19544720167cb57ffae0079873d350c27432d55c7a1bc442759b979b242ebbe6"
    }
  },
  {
    "ts": null,
    "headline": "How I Would Build An Ultra-High-Conviction Retirement Portfolio Right Now",
    "summary": "Build a resilient retirement portfolio with disruption-resistant income, growth stocks, and ETFs. Read the full article here.",
    "url": "https://finnhub.io/api/news?id=1b6afff1c0470663170fb6cb70c8fca876d2574c05f44db7bb82ff6f9f098aa0",
    "source": "SeekingAlpha",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1759476600,
      "headline": "How I Would Build An Ultra-High-Conviction Retirement Portfolio Right Now",
      "id": 136963531,
      "image": "https://static.seekingalpha.com/cdn/s3/uploads/getty_images/1800519398/image_1800519398.jpg?io=getty-c-w1536",
      "related": "LLY",
      "source": "SeekingAlpha",
      "summary": "Build a resilient retirement portfolio with disruption-resistant income, growth stocks, and ETFs. Read the full article here.",
      "url": "https://finnhub.io/api/news?id=1b6afff1c0470663170fb6cb70c8fca876d2574c05f44db7bb82ff6f9f098aa0"
    }
  },
  {
    "ts": null,
    "headline": "Pfizer’s Drug-Price Deal With Trump Followed Months of Deadlock",
    "summary": "The post, however, played a critical role in cementing a deal with one of the world’s largest pharmaceutical companies, Pfizer Inc., according to senior officials from the White House and the Centers for Medicare and Medicaid Services who requested anonymity to discuss the inner workings of the process.  For months, Pfizer and the White House had been deadlocked in their negotiations over how to address one of President Trump’s most critical issues: lowering US drug prices.",
    "url": "https://finnhub.io/api/news?id=4d1c7cfc5cd19212043a831463c038f2561f05103374276a8361b14d44fbc704",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1759457507,
      "headline": "Pfizer’s Drug-Price Deal With Trump Followed Months of Deadlock",
      "id": 136962268,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "LLY",
      "source": "Yahoo",
      "summary": "The post, however, played a critical role in cementing a deal with one of the world’s largest pharmaceutical companies, Pfizer Inc., according to senior officials from the White House and the Centers for Medicare and Medicaid Services who requested anonymity to discuss the inner workings of the process.  For months, Pfizer and the White House had been deadlocked in their negotiations over how to address one of President Trump’s most critical issues: lowering US drug prices.",
      "url": "https://finnhub.io/api/news?id=4d1c7cfc5cd19212043a831463c038f2561f05103374276a8361b14d44fbc704"
    }
  }
]